orchid bio. wieder einsteigen? - 500 Beiträge pro Seite

[semydeluxe]

hallo leute ,
was haltet ihr von orch ?
am 27.02 kommen die zahlen.
was haltet ihr vom chart ,würdet ihr jetzt einsteigen?
bitte um antwort.

mfg.semy

[Elrond]

bin schon seit Wochen drin

ich glaube ich schmeiße am Montag - iss mir zu langweilig

[suncomesout]

Halli,

bin schon ne ganze Weile drin und beobachte die Bude. Sicher nach wie vor ziemlich risikoreich. Es könnte einem doch zu denken geben, daß die in der letzten Zeit praktisch kein Patent mehr bekommen haben. Andererseits müßte es doch auch mal wieder für die Bios aufwärts gehen.
Suncomesout

[Bombenleger]

ich bin auch dabei. die zahlen finde ich gut. geht weiter aufwärts. denke das es die nächsten
zahlen bestätigen werden.

[suncomesout]

Soooo. Nun ists bald soweit. Morgen ist Tag des Herrn (der Zahlen). Hopp oder Top, das ist hier die Frage...
Gutes Nächtle an alle, die noch investiert sind.

Suncomesout

[Elskea]

Hallo zusammen,

In Frankfurt + 25% !
Was geht da ab ?

Gruß
Elskea

PS.
War auf der Homepage von OHS(www.orchid.com),leider ist mein englisch nicht ganz so gut.
Ich meine aber,daß die Zahlen zum Geschäfts-Jahresende anstehen.(05.04.)

[suncomesout]

@Elskea

Die Jahreszahlen und 4Q02-Zahlen sind seit 27.2. bekannt (und waren ziemlich mittelmäßig). Daran liegts nicht. Aber: OHS hat wohl von der NASDAQ die vorläufige Zusage bekommen, bis Juni nicht delistet zu werden. Außerdem haben sie nen 16 Mio$-Finanzierungsdeal gerade erfolgreich abgeschlossen. Und da hat so mancher (ich auch) jetzt die begründete Hoffnung, dass es aufwärts geht.

[Elskea]

@suncomesout
Danke für Deine Erläuterungen.
Bin schon einige Zeit in OHS "drin" und hoffe nun,wie Du,
daß es weiter aufwärts geht.
Gruß
Elskea

[BigTsunami]

Wow, was ist denn mit ORCHID los? +15% in FRA seit heute morgen. Weiss einer mehr?

BT

[orkadian]

Orch hat Vertrag mit Scotland Yard abgeschlossen...

[Elskea]

@suncomesout

heute in München gehandelte Stücke 58.786
Kurs 1,34 plus 14,53 %

Ich bleibe weiterhin investiert!

Gruß
Elskea

[suncomesout]

@Elskea
Im Hinblick auf die Infos der letzten Monate MUSS man glaube ich auch investiert bleiben. Der Scotland Yard-Vertrag könnte ja durchaus eine erhebliche Sogwirkung haben. Und die finanzielle Situation scheint zumindest im Moment stabilisiert zu sein...
Da gibts doch viel wackligere Investments...

Grüsse,

Suncomesout

[BigTsunami]

@Suncomesout

Das sind ja schoene Zahlen heute. Meinst Du das sich ein Einstieg jetzt lohnt?

BT

[Elskea]

Hallo Suncomesout,

ich habe erst gedacht,daß die Meldung,bezüglich Scotland Yard ein "Witz" ist.
Was hat denn Scotland Yard mit Orchid zu tun ?
Weißt Du näheres ?

Gruß
Elskea

[suncomesout]

@ELSKEA
Moin.
Nein, das ist mit Gewissheit kein Witz. Die können mit ihrer Gensequenzierung einiges zur Verbesserung in der Forensik beisteuern. Denk doch nur an die Verbrecher, die in den letzten Jahren immer häufiger durch Genanalyse überführt wurden. Von der Einrichtung einer genetischen Datenbank mal ganz zu schweigen.
Könnte mir glatt vorstellen, dass der Vertrag mit SY eine erhebliche Sogwirkung hat.

Schönen Tag,

Suncomesout

[VonHinten]

handel nimmt zu ... könnte ausbrechen

[suncomesout]

Aktuelle Entwicklung:

Orchid BioSciences Announces Conversion of Preferred Stock and Provides Financial Guidance Update


PRINCETON, N.J., Feb. 10 /PRNewswire-FirstCall/ -- Orchid BioSciences, Inc. (Nasdaq: ORCH) today announced that all of its outstanding convertible preferred stock has been converted into common stock. As a result, Orchid had approximately 94.7 million common shares outstanding as of February 9, 2004. Additionally, Orchid provided an update to its financial guidance for 2003 and 2004.

"In view of the many near-term growth opportunities facing Orchid, I believe the next step in our restructuring is to further strengthen our capital structure in order to better position the company for profitable growth," said Paul J. Kelly, M.D., chief executive officer of Orchid. "With completion of this initial phase of our capital restructuring effort, we look forward to the next phases, which we expect will include our proposed reverse stock split and, at an appropriate time, raising additional capital to help fund Orchid`s next phase of growth."

Orchid re-affirmed and expanded its financial guidance for the full year 2003 and for 2004:

2003 Financial Guidance Update
-- Orchid continues to expect top-line revenues of approximately $50
million for the full year 2003.
-- Orchid estimates that its 2003 year-end free cash balance will be
approximately $10 million, which includes $1 million of the $3.45
million purchase price paid to Orchid in connection with the sale of
its Diagnostics unit. This estimate differs from the company`s
previous guidance of $11 million to $13 million because the
transaction closed in January 2004 and as a result the full purchase
price could not be recorded in 2003.
-- Orchid expects its average gross margin to be in the low-to-mid 40
percent range for the full year 2003.

2004 Financial Guidance Update
-- Orchid expects an increase in its 2004 top-line revenues of
approximately 20 percent over its expected 2003 top-line revenues.
-- Orchid expects its 2004 average gross margin to improve by
approximately 2 to 4 percentage points over its expected 2003 gross
margins.
-- Orchid expects its full year 2004 total operating expenses to decrease
by approximately 10 percent compared to its expected total operating
expenses for 2003.
-- Orchid continues to expect to achieve positive cash flows from
operations in the first half of 2004.
-- Orchid expects to achieve positive operating income for the full year
2004.

Fourth Quarter and Full Year 2003 Financial Results

Orchid`s fourth quarter and full year 2003 financial results are scheduled to be released on Thursday, February 26, 2004, and an investor conference call with management will be held that morning to discuss the financial results and recent operating highlights as well as 2004 guidance. The company will announce the call details on or about February 19, 2004.

Reverse Stock Split

As previously announced, Orchid is seeking shareholder approval to implement a reverse stock split ranging from 1-for-3 shares to 1-for-7 shares. A Special Meeting of Shareholders will be held on February 27, 2004 to consider this proposal.

SCO

[suncomesout]

Wow!
Topstocks der letzten 24 Stunden

1. PROVIDENTIAL HLDGS ... 100
2. TOURNIGAN GOLD COR 69
3. NEWTECH RESOURCES LT... 39
4. DEUTSCHE ENTERTAINME... 34
5. QSC AG 32
6. UNIVERSAL EXPRESS IN... 22
7. MLP AG 21
8. IM INTERNATIONALMEDI... 21
9. ORCHID BIOSCIENCES, ... 20
10. OBDUCAT AB 19
11. WCM BETEILIGUNGS-UND... 16
12. FREENET.DE AG 16
13. Realtos Grund- und B... 16
14. AMBRI LTD 16
15. MORPHOSYS AG 14



SCO

[Paepstin]

Das ist jetzt für alle:

Topstocks der letzten 24 Stunden

1. PROVIDENTIAL HLDGS ... 109
2. TOURNIGAN GOLD COR 70
3. ORCHID BIOSCIENCES, ... 48
4. NEWTECH RESOURCES LT... 41


Päpstin, immer zu Diensten

[suncomesout]

Damit alle wissen, worums heute geht:

Orchid BioSciences to Host Conference Call to Announce Fourth Quarter and Full Year 2003 Financial Results


PRINCETON, N.J., Feb. 19 /PRNewswire-FirstCall/ -- Orchid BioSciences, Inc. (Nasdaq: ORCH) will release its fourth quarter and full year 2003 financial results before the U.S. financial markets open on Thursday, February 26, 2004 and is hosting a conference call that also will be broadcast live over the Internet that day at 10:00 a.m. ET. Participating members of Orchid senior management include Paul J. Kelly, M.D., chief executive officer and Michael E. Spicer, chief financial officer. Management will discuss financial results for the fourth quarter and full year 2003 as well as Orchid`s recent operating highlights. A question-and-answer session will follow management`s discussion.
What: Orchid BioSciences, Inc. Fourth Quarter and Full Year 2003 Financial Results Conference Call
When: Thursday, February 26, 2004, 10:00 a.m. ET
How: The dial-in number is 1-973-317-1168
A live Webcast of the conference call and a replay will also be available via the Investor Relations section of the company`s website at www.orchid.com. All interested parties are encouraged to listen to the live conference call or the live or archived Webcast.


Suncomesout

[Paepstin]

[suncomesout]

Orchid Awarded Immigration Identity Testing Contract by New Zealand Government


Further Expands Orchid`s International Immigration Testing Services

PRINCETON, N.J. and ABINGDON, England, April 13 /PRNewswire-FirstCall/ -- Orchid BioSciences, Inc. (Nasdaq: ORCHD) today announced that its Orchid Europe operation has been awarded an exclusive DNA analysis contract by the New Zealand Immigration Service. Orchid will provide DNA testing services to individuals seeking to migrate to New Zealand, when they cannot establish their identities and biological relationships by conventional means. This three-year contract was awarded to Orchid following a competitive bid process and is potentially renewable for an additional two years. Further details were not disclosed.

" It is critical that an approved and reliable system of DNA analysis be available to assist residence applicants where documentation to establish the necessary relationships between themselves and their sponsors does not exist or is unreliable," said Gill Johnson of the New Zealand Immigration Service. " We believe Orchid can deliver what we require and we are looking forward to working with them."

Orchid, which markets several of its services under the Cellmark brand, will provide DNA testing services under the contract to determine the biological relationships between applicants and their family members, including sponsors in New Zealand . Like most countries, New Zealand allows immigration of certain relatives of its citizens and permanent residents. DNA testing is particularly important for applicants from countries that do not have records systems that enable applicants to otherwise satisfy the New Zealand Immigration Service of the necessary family relationships.

" DNA relationship analysis is increasingly being used as part of government immigration programs and often requires the complex analysis that we specialize in," said David Hartshorne, commercial director of Orchid Europe. " Orchid has an established reputation for quality and accurate testing and is at the forefront of developing new technologies and services to assess claimed relationships. We are delighted to be the provider of choice for the New Zealand Immigration Service."

In addition to this contract with the New Zealand Immigration Service, Orchid is also the exclusive provider of immigration DNA testing for the UK government`s UKVisa`s program, and the sole supplier to the Norwegian government`s immigration department. Work under this contract will be provided at Orchid`s Abingdon facility in the U.K.